Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
INTERVENTIONAL
2001-12-31
2007-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
PURPOSE: Phase I trial to determine the dose amount of curcumin that can be tolerated to help in preventing colon cancer in healthy men and women.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* Determine the maximum tolerated dose (MTD) of curcumin as a chemopreventive agent of colon cancer in healthy subjects.
* Determine if tolerable doses of this agent in uniformly milled formulation capsules are bioavailable in these subjects.
* Determine the pharmacokinetics of this agent and two metabolites at the MTD and next lower escalated dose in these subjects.
OUTLINE: This is a dose escalation study followed by a pharmacokinetic study.
Patients receive a single oral dose of curcumin followed by a standard fatty meal.
Cohorts of 3-6 patients receive escalating doses of curcumin until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which 2 of 6 patients experience dose limiting toxicities. Once the MTD is determined, additional patients are accrued to receive curcumin in the pharmacokinetic phase of the study.
Patients are followed at 24, 36, 48, and 72 hours.
PROJECTED ACCRUAL: A total of 3-24 patients will be accrued for the dose escalation phase and then 12 additional patients will be accrued for the pharmacokinetic phase of this study within 3 months.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
PREVENTION
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
curcumin
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Healthy men and women age 18 and over
PATIENT CHARACTERISTICS:
Age:
* 18 and over
Performance status:
* Not specified
Life expectancy:
* Not specified
Hematopoietic:
* WBC greater than 4,000/mm3
* Hemoglobin greater than 12 g/dL
* Platelet count greater than 120,000/mm3
Hepatic:
* ALT/AST less than 1.5 times upper limit of normal (ULN)
* Alkaline phosphatase less than 1.5 times ULN
* Bilirubin less than 1.5 mg/dL
Renal:
* Creatinine less than 1.7 mg/dL
Other:
* Not pregnant or nursing
* Negative pregnancy test
* Fertile patients must use effective contraception
* No prior cancer except surgically resected basal cell or squamous cell skin cancer
* No history of peptic ulcer disease, gastrointestinal bleeding from gastric or duodenal ulcers, or gastrin secreting tumors
* No history of unreliability or noncompliance (missing pretreatment appointment more than twice)
PRIOR CONCURRENT THERAPY:
Biologic therapy:
* Not specified
Chemotherapy:
* Not specified
Endocrine therapy:
* At least 14 days since prior steroids
Radiotherapy:
* Not specified
Surgery:
* Not specified
Other:
* At least 14 days since prior curcumin (turmeric) rich foods
* At least 14 days since prior nonsteroidal antiinflammatory drugs (NSAIDs)
* No chronic medications (i.e., daily for more than 28 days) except for oral contraceptives
* No concurrent coumadin or other anticoagulants
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
University of Michigan Rogel Cancer Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Dean E. Brenner, MD
Role: STUDY_CHAIR
University of Michigan Rogel Cancer Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CCUM-9941
Identifier Type: OTHER
Identifier Source: secondary_id
NCI-P00-0144
Identifier Type: -
Identifier Source: secondary_id
CDR0000067916
Identifier Type: -
Identifier Source: org_study_id